Zentalis (ZNTL) Director David M. Johnson Receives Award

What Happened
David Michael Johnson, a director of Zentalis Pharmaceuticals (ZNTL), was granted 57,100 restricted stock units (RSUs) on June 16, 2026. The Form 4 reports the acquisition as 57,100 shares at $0.00 (transaction code A — award/grant), so no cash purchase was involved. These RSUs represent contingent rights to receive one share of common stock per unit upon vesting.

Key Details

• Transaction date: 2026-06-16; Form 4 filed: 2026-06-18 (timely filing).
• Grant: 57,100 RSUs; reported price: $0.00; total reported value on Form 4: $0.
• Vesting: RSUs vest on the earlier of (a) June 16, 2027 or (b) the next annual meeting of stockholders, subject to continued service on the Board (per footnote).
• Shares owned after transaction: not specified in the provided filing summary.
• Footnotes/Exhibits: F1 describes the RSU vesting conditions; Exhibit 24 is a Power of Attorney.
• Transaction code: A = Award/Grant (non-purchase, non-sale).

Context
These RSUs are director compensation and are contingent on continued board service until vesting; they do not represent immediately transferable shares and required no cash outlay. Such grants are routine for non-employee directors and should be interpreted as compensation rather than a clear bullish or bearish signal by the insider.